Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Coeptis Therapeutics Holdings (COEPW) Operating Leases (2022 - 2025)

Coeptis Therapeutics Holdings has reported Operating Leases over the past 4 years, most recently at $29865.0 for Q3 2025.

  • Quarterly results put Operating Leases at $29865.0 for Q3 2025, down 57.98% from a year ago — trailing twelve months through Sep 2025 was $29865.0 (down 57.98% YoY), and the annual figure for FY2024 was $18875.0, down 69.15%.
  • Operating Leases for Q3 2025 was $29865.0 at Coeptis Therapeutics Holdings, down from $40612.0 in the prior quarter.
  • Over the last five years, Operating Leases for COEPW hit a ceiling of $71069.0 in Q3 2024 and a floor of $14723.0 in Q4 2022.
  • Median Operating Leases over the past 4 years was $43448.0 (2023), compared with a mean of $40456.4.
  • Peak annual rise in Operating Leases hit 382.71% in 2024, while the deepest fall reached 69.15% in 2024.
  • Coeptis Therapeutics Holdings' Operating Leases stood at $14723.0 in 2022, then skyrocketed by 315.53% to $61179.0 in 2023, then crashed by 69.15% to $18875.0 in 2024, then soared by 58.23% to $29865.0 in 2025.
  • The last three reported values for Operating Leases were $29865.0 (Q3 2025), $40612.0 (Q2 2025), and $51065.0 (Q1 2025) per Business Quant data.